Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Effect of Rosiglitazone on Circulating Malondialdehyde (Mda) Level in Diabetes Based on a Systematic Review and Meta-Analysis of Eight Clinical Trials Publisher Pubmed



Majidi Z1 ; Hosseinkhani S1 ; Amiridashatan N2 ; Emamgholipour S1 ; Tutunchi S3 ; Hashemi J4 ; Ghorbani F1 ; Koushki M5
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Clinical Biochemistry, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Proteomics Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  3. 3. Department of Medical Genetics, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
  4. 4. Department of Pathobiology and Laboratory Sciences, School of Medicine, North Khorasan University of Medical Sciences, Bojnord, Iran
  5. 5. Department of Clinical Biochemistry, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran

Source: Journal of Investigative Medicine Published:2021


Abstract

Patients with type 2 diabetes have high levels of malondialdehyde (MDA), and clinical data suggest a reducing effect of rosiglitazone (RSG) on the level of MDA in these patients. However, the results of available studies on the level of MDA in RSG-treated patients are not univocal. This meta-analysis aimed to assess the impact of RSG on the level of MDA. We performed a comprehensive search of PubMed, the Institute for Scientific Information Web of Science, Embase, Scopus, and Cochrane Library for related controlled trials until July 2020. Eligible studies were selected based on the inclusion criteria. Extracted data from each study were combined using a random-effects model. Sensitivity and subgroup analyses were conducted to explore potential heterogeneity. Eight trials with 456 subjects met the inclusion criteria. The results significantly showed the reducing effect of RSG on circulating MDA level (-0.47 mol/mL; 95% CI -0.93 to -0.01; p=0.04; I 2 =82.1%; p heterogeneity=0.00) in individuals with T2D. No publication bias was observed with Begg's rank correlation (p=0.71) and Egger's linear regression (p=0.52) tests. Subgroup analyses showed that an intervention dose of 8 mg/day in serum samples was found to have a reducing effect on the level of MDA (-0.56 mol/mL; 95% CI -0.98 to -0.14; p=0.008; I 2 =11.4%; p heterogeneity=0.32). Random-effects meta-regression did not show any significant association between the level of MDA and potential confounders including RSG dose, treatment duration, and sex. In conclusion, we found a significant reduction in MDA concentration in subjects with T2D who received a dose of 8 mg of RSG daily. © American Federation for Medical Research 2021.No commercial re-use.See rights and permissions.Published by BMJ.
Experts (# of related papers)
Other Related Docs
38. Prevalence of Preeclampsia and Eclampsia in Iran, Archives of Iranian Medicine (2016)